![](/img/cover-not-exists.png)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, SVolume:
102
Year:
2010
Language:
english
Pages:
7
DOI:
10.1038/sj.bjc.6605507
File:
PDF, 318 KB
english, 2010